These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 36123122)

  • 1. Association of MRI Indices of Glymphatic System With Amyloid Deposition and Cognition in Mild Cognitive Impairment and Alzheimer Disease.
    Kamagata K; Andica C; Takabayashi K; Saito Y; Taoka T; Nozaki H; Kikuta J; Fujita S; Hagiwara A; Kamiya K; Wada A; Akashi T; Sano K; Nishizawa M; Hori M; Naganawa S; Aoki S;
    Neurology; 2022 Dec; 99(24):e2648-e2660. PubMed ID: 36123122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease.
    Huang SY; Zhang YR; Guo Y; Du J; Ren P; Wu BS; Feng JF; ; Cheng W; Yu JT
    Alzheimers Dement; 2024 May; 20(5):3251-3269. PubMed ID: 38501315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A "glympse" into neurodegeneration: Diffusion MRI and cerebrospinal fluid aquaporin-4 for the assessment of glymphatic system in Alzheimer's disease and other dementias.
    Sacchi L; D'Agata F; Campisi C; Arcaro M; Carandini T; Örzsik B; Dal Maschio VP; Fenoglio C; Pietroboni AM; Ghezzi L; Serpente M; Pintus M; Conte G; Triulzi F; Lopiano L; Galimberti D; Cercignani M; Bozzali M; Arighi A
    Hum Brain Mapp; 2024 Aug; 45(12):e26805. PubMed ID: 39185685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glymphatic system impairment in Alzheimer's disease: associations with perivascular space volume and cognitive function.
    Zhang X; Wang Y; Jiao B; Wang Z; Shi J; Zhang Y; Bai X; Li Z; Li S; Bai R; Sui B
    Eur Radiol; 2024 Feb; 34(2):1314-1323. PubMed ID: 37610441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between amyloid pathology, cerebral small vessel disease, glymphatic dysfunction, and cognition: a study based on Alzheimer's disease continuum participants.
    Hong H; Hong L; Luo X; Zeng Q; Li K; Wang S; Jiaerken Y; Zhang R; Yu X; Zhang Y; Lei C; Liu Z; Chen Y; Huang P; Zhang M;
    Alzheimers Res Ther; 2024 Feb; 16(1):43. PubMed ID: 38378607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroimaging findings related to glymphatic system alterations in older adults with metabolic syndrome.
    Andica C; Kamagata K; Takabayashi K; Kikuta J; Kaga H; Someya Y; Tamura Y; Kawamori R; Watada H; Taoka T; Naganawa S; Aoki S
    Neurobiol Dis; 2023 Feb; 177():105990. PubMed ID: 36621631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
    Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
    J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired Glymphatic Flow on Diffusion Tensor MRI as a Marker of Neurodegeneration in Alzheimer's Disease: Correlation with Gray Matter Volume Loss and Cognitive Decline Independent of Cerebral Amyloid Deposition.
    Kim M; Song YS; Han K; Bae YJ; Han JW; Kim KW
    J Alzheimers Dis; 2024; 99(1):279-290. PubMed ID: 38669532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET/MRI multimodality imaging to evaluate changes in glymphatic system function and biomarkers of Alzheimer's disease.
    Okazawa H; Nogami M; Ishida S; Makino A; Mori T; Kiyono Y; Ikawa M
    Sci Rep; 2024 May; 14(1):12310. PubMed ID: 38811627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
    Hatashita S; Yamasaki H
    PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
    Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
    ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffusion MRI relates to plasma Aβ42/40 in PET negative participants without dementia.
    DeSimone JC; Wang WE; Loewenstein DA; Duara R; Smith GE; McFarland KN; Armstrong MJ; Weber DM; Barker W; Coombes SA; Vaillancourt DE
    Alzheimers Dement; 2024 Apr; 20(4):2830-2842. PubMed ID: 38441274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI-Visible Perivascular Spaces in the Centrum Semiovale Are Associated with Brain Amyloid Deposition in Patients with Alzheimer Disease-Related Cognitive Impairment.
    Kim HJ; Cho H; Park M; Kim JW; Ahn SJ; Lyoo CH; Suh SH; Ryu YH
    AJNR Am J Neuroradiol; 2021 Jul; 42(7):1231-1238. PubMed ID: 33985952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Precuneus - A Witness for Excessive Aβ Gathering in Alzheimer's Disease Pathology.
    Aghakhanyan G; Vergallo A; Gennaro M; Mazzarri S; Guidoccio F; Radicchi C; Ceravolo R; Tognoni G; Bonuccelli U; Volterrani D
    Neurodegener Dis; 2018; 18(5-6):302-309. PubMed ID: 30814473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intra-individual correlations between quantitative THK-5351 PET and MRI-derived cortical volume in Alzheimer's disease differ according to disease severity and amyloid positivity.
    Park JE; Yun J; Kim SJ; Shim WH; Oh JS; Oh M; Roh JH; Seo SW; Oh SJ; Kim JS
    PLoS One; 2019; 14(12):e0226265. PubMed ID: 31834916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.